#ERBB2)
LightNews LightNews
oncodaily.bsky.social
Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients

oncodaily.com/insight/259722

#Cancer #NSCLC #OncoDaily #Oncology #Medicine #Health #MedOnc #MedX #MedNews #MedEd
Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients - OncoDaily
Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients / cancer, Erick F. Saldanha, NSCLC, OncoDaily, Oncology
oncodaily.com
March 29, 2025 at 1:05 PM
stoverlab.bsky.social
Small but interesting single arm study -
Intratumoral delivery of dendritic cells + anti-HER2 antibodies alone resulted in complete responses in 3 of 12 patients!

Congrats to Heather Han & colleagues at Moffitt.

jamanetwork.com/journals/jam...
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer
This nonrandomized clinical trial examines the safety, immunogenicity, and preliminary efficacy of intratumoral delivery of conventional type 1 dendritic cells in combination with ERBB2-targeted thera...
jamanetwork.com
December 5, 2024 at 9:41 PM
greisinglab.bsky.social
Happy to share this @jphysiol.bsky.social paper from our group as we work to find novel approaches to improve muscle innervation after injury physoc.onlinelibrary.wiley.com/doi/10.1113/...
Inhibition of ErbB2 mitigates secondary denervation after traumatic muscle injury
Abstract figure legend Our study evaluated the therapeutic potential of ErbB2 inhibition (Herceptin) after volumetric muscle loss (VML) injury, primarily evaluating improvements at the neuromuscular ...
physoc.onlinelibrary.wiley.com
March 4, 2025 at 3:06 PM
rielymd.bsky.social
Herbert Loong presenting data on Sevabertinib in ERBB2/HER2 mutated NSCLC #ASCO25
Cohort with no prior treatment and another with no prior HER2 targeted therapy.
June 1, 2025 at 2:19 PM
sudkrishnamurthy.bsky.social
📋‼️Honored to share this newly published article that I helped lead!

Cannot thank @uressien.bsky.social enough - he has served as a friend, mentor, and sponsor throughout! And the whole study team who this wouldn’t have happened without!🙏🏽

Will post a longer thread on the findings soon - stay tuned!
This image is a visual abstract for a paper titled ‘Racial and Ethnic Disparities in Receipt of ERBB2-Targeted Therapy for Breast Cancer, 2010-2020”. This was a Retrospective Cohort study using a SEER-Medicare Linked Dataset. The sample comprised 12,765 beneficiaries with ERBB2-positive breast cancer, and included those diagnosed from January 2010 to December 2020. The primary outcome of the study was receipt of ERBB2-targeted therapy in 12 months after diagnosis. The primary findings showed a) an increase in overall receipt of ERBB2-targeted therapies from 41.3% to 64.3% over time, and that b) Black & Hispanic patients had a lower likelihood of receipt than White patients in 2010-11, with no differences by 2018-19. The findings suggest a narrowing of racial and ethnic disparities in receipt of therapies over time among older Medicare beneficiaries with ERBB2-positive breast cancer. Future work is needed to understand the practices that resulted in the narrowing of disparities to develop implementation strategies and improve pharmacoequity in breast cancer care.
May 5, 2025 at 9:32 PM
laosaal.bsky.social
Our new publication online today on dPCR quantification of “#ultrahigh” #HER2 #ERBB2 copy number in early #breastcancer and association to poor response to #trastuzumab. Nice work by #pei_meng #heena_dilal @brueffer.io #sergii_gladchuk #anna_ehinger et al www.nature.com/articles/s41...
Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab - npj Breast Cancer
npj Breast Cancer - Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab
www.nature.com
February 19, 2024 at 9:39 PM
medrxivpreprint.bsky.social
Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases https://www.medrxiv.org/content/10.1101/2025.02.19.25322558v1
February 27, 2025 at 2:40 AM
sudkrishnamurthy.bsky.social
In the meantime, if you’d like to give it a read, here’s the link to the article!

jamanetwork.com/journals/jam...

#Pharmacoequity
Racial and Ethnic Disparities in Receipt of ERBB2-Targeted Therapy for Breast Cancer
This cohort study examines racial and ethnic disparities in the receipt of ERBB2 (formerly HER2 or HER2/neu)–targeted therapies and changes in receipt over time among Medicare beneficiaries with ERBB2...
jamanetwork.com
May 5, 2025 at 9:32 PM
sigtrans-sttt.bsky.social
Full-length #Transcriptome atlas of #GallbladderCancer reveals that ERBB2 alternative splicing mediates trastuzumab resistance in gallbladder cancer, highlighting alternative splicing as a key #TherapeuticTarget.
#STTT #OpenAccess: doi.org/10.1038/s413...
Full-length transcriptome atlas of gallbladder cancer reveals trastuzumab resistance conferred by ERBB2 alternative splicing
May 10, 2026 at 3:30 PM
drdavidmcmahon.bsky.social
Pleased to publish a case report exploring a number of interesting elements of ERBB2 (HER2) mutated NSCLC on @jtoonline.bsky.social with @drsanjaypopat.bsky.social and @dralexiusjohn.bsky.social
www.jtocrr.org/article/S266...
Acquired ERBB2 amplification and overexpression as on-target resistance mechanisms to zongertinib with subsequent response to trastuzumab deruxtecan; a case report
A number of drugs are in development for the treatment of ERBB2(HER2)-mutated Non-Small Cell Lung Cancer (NSCLC) including antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) and ty...
www.jtocrr.org
January 24, 2026 at 12:31 PM
sudkrishnamurthy.bsky.social
Sharing a short thread here on our recent publication from earlier this month. This project was an incredible team effort, and truly would not have been possible without every co-author on this all-⭐ team!

Go give it a read here if interested: jamanetwork.com/journals/jam...

A short 🧵:

(1/x)
This image is a visual abstract for a paper titled ‘Racial and Ethnic Disparities in Receipt of ERBB2-Targeted Therapy for Breast Cancer, 2010-2020”. This was a Retrospective Cohort study using a SEER-Medicare Linked Dataset. The sample comprised 12,765 beneficiaries with ERBB2-positive breast cancer, and included those diagnosed from January 2010 to December 2020. The primary outcome of the study was receipt of ERBB2-targeted therapy in 12 months after diagnosis. The primary findings showed a) an increase in overall receipt of ERBB2-targeted therapies from 41.3% to 64.3% over time, and that b) Black & Hispanic patients had a lower likelihood of receipt than White patients in 2010-11, with no differences by 2018-19. The findings suggest a narrowing of racial and ethnic disparities in receipt of therapies over time among older Medicare beneficiaries with ERBB2-positive breast cancer. Future work is needed to understand the practices that resulted in the narrowing of disparities to develop implementation strategies and improve pharmacoequity in breast cancer care.
May 23, 2025 at 9:22 PM
wonkish.bsky.social
Dear god: "an 80% overall response rate. All patients with ERBB2-positive or hormone receptor–negative DCIS experienced at least a partial response, with one-third experiencing complete resolution of the tumor,"

And the side effects just sound like regular mild temporary vaccine side effects.
February 11, 2026 at 4:16 PM
oncodaily.bsky.social
Insights into HER2-low breast cancers - Paolo Cotzia

oncodaily.com/blog/227609

#BreastCancer #Treatment #Cancer #CancerGenomics #ERBB2MRNAExpression #FluorescenceInSituHybridization #HER2-LowBreastCancer #Immunohistochemistry #MolecularOncology #OncoDaily #Oncology #Health #Medicine
Paolo Cotzia: Insights into HER2-low breast cancers - OncoDaily
Paolo Cotzia: Insights into HER2-low breast cancers / breast cancer treatment, cancer, cancer genomics, ERBB2 mRNA expression, estrogen receptor signaling,
oncodaily.com
January 21, 2025 at 1:11 PM
scientistswanda.bsky.social
HER2‑mutant metastatic NSCLC is a unique form of lung cancer driven by specific changes in the ERBB2 gene that make cancer cells grow aggressively. These mutations act like a stuck accelerator pedal, sending nonstop growth signals. Learn more in my latest video!
youtu.be/M5wa8ld19LA
Overview of HER2 (ERBB2) Mutant Metastatic NSCLC
YouTube video by Dr. Rob Swanda
youtu.be
July 20, 2026 at 7:24 PM
boehringerglobal.bsky.social
#NEWS: New data available in HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC) in patients with stable, asymptomatic, and active brain metastases – underscoring our commitment to patients’ greatest needs.  🧪

Learn more about our presentation at #WCLC25: go.boehringer.com/WdAhL
September 8, 2025 at 2:38 PM
uressien.bsky.social
‼️ NEW Paper.

Led by @sudkrishnamurthy.bsky.social we found wide disparities in receipt of ERBB2-targeted 💊 for Medicare enrollees w. breast cancer, disparities that did narrow by 2019.

We need more research to identify strategies to improve cancer #Pharmacoequity.

jamanetwork.com/journals/jam...
May 2, 2025 at 4:08 PM
boehringerglobal.bsky.social
#NEWS: Today, the @fda.gov approved our orally administered therapy for patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment. This marks the first approved targeted therapy for this use.

Learn more: go.boehringer.com/VHCH-

#LifeForward
February 26, 2026 at 6:46 PM
mskeducation.bsky.social
Congrats Sharanya! Her Clinical Cancer Research study identified ERBB2 mutations as a biomarker of trastuzumab deruxtecan response, potentially expanding treatment options for patients with breast cancer. Featured at @theaacr.bsky.social D3 2026 and highlighted in AACR's From the Bench series. 👏
October 1, 2026 at 5:30 PM
mcbridetd.bsky.social
Breast Cancer Therapy Disparities Decline www.medscape.com/viewarticle/...
Breast Cancer Therapy Disparities Decline
Racial gaps in the use of ERBB2-targeted therapy among older Medicare beneficiaries with breast cancer reduced significantly from 2010 to 2019, a new study finds.
www.medscape.com
May 5, 2025 at 6:14 PM
micropub7n.bsky.social
MEMO1–ERα interaction may occur independent of Y537 phosphorylation which differs from MEMO1-ErbB2 binding #micropublication #biology #data #caltechlibrary #Escherichiacoli #Biochemistry #Computationa https://micropublication.org/journals/biology/micropub-biology-002363
Figure 1
September 29, 2026 at 6:40 PM
cancergrand.bsky.social
#CancerGrandChallenges IMAXT in @nature.com:
Using CloneSeq-SV, the team tracked ovarian cancer clones and found:

• Resistant clones often exist from diagnosis
• ctDNA spotted recurrence ~8 months earlier than imaging
• Actionable drivers (e.g. ERBB2) can be revealed

www.nature.com/articles/s41...
October 3, 2025 at 12:35 PM
jamaoncology.com
Adding atezolizumab to trastuzumab and XELOX #chemotherapy increased the pathological complete response rate in Chinese patients with locally advanced ERBB2-positive gastric or gastroesophageal junction #cancer.

ja.ma/3HJDeem

#OncSky
July 4, 2025 at 1:56 AM
drdavidmcmahon.bsky.social
We explore:
- Response to zongertinib
- Acquired ERBB2 over expression and amplification
- Subsequent near complete response to T-DXd
- Potential rationale for T-DXd/TKI combination strategies in the future
January 24, 2026 at 12:36 PM
alfredodistefano.bsky.social
This meta-analysis found that trastuzumab emtansine was associated with the lowest incidence of LVEF decrease.

#breastcancer #her2 #oncology

jamanetwork.com/journals/jam...
Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced BC
This systematic review and meta-analysis compares the incidence of cardiotoxic effects of antibody-drug conjugates vs standard chemotherapy regimens for erb-b2 receptor tyrosine kinase 2 (ERBB2)–posit...
jamanetwork.com
November 12, 2025 at 11:46 AM
onco404.bsky.social
5️⃣ ERBB2-dependent (ERBB2-D): Driven by high ERBB2 expression and signaling pathways.

These findings highlight the heterogeneity 🎨 of HER2-positive BC and emphasize the potential of tailored treatment strategies that address both tumor-intrinsic and microenvironment features 🎯

#Onco404 #Cancer
March 25, 2025 at 8:15 AM